Liquidia (NASDAQ:LQDA) Insider Sells 688 Shares of Company Stock

Key Points

• Liquidia insider Jason Adair sold 688 shares at an average price of $43.19, generating $29,714.72. The sale, conducted under a Rule 10b5-1 plan, covered tax withholding obligations tied to vested equity awards; Adair retained 177,269 shares.
• Liquidia shares rose 0.6% to $45.72, while the company reported quarterly revenue of $171.68 million, up 1,842.1% year over year, but earnings per share of $0.74 narrowly missed analyst expectations.
• Analyst sentiment remains mixed, with a consensus “Hold” rating and an average price target of $72.85. Institutional investors own approximately 64.54% of the company.

Liquidia Corporation (NASDAQ:LQDA - Get Free Report) insider Jason Adair sold 688 shares of the firm's stock in a transaction that occurred on Monday, October 26th. The shares were sold at an average price of $43.19, for a total value of $29,714.72. Following the sale, the insider owned 177,269 shares of the company's stock, valued at approximately $7,656,248.11. This trade represents a 0.39% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jason Adair also recently made the following trade(s):

• On Monday, October 12th, Jason Adair sold 7,301 shares of Liquidia stock. The shares were sold at an average price of $28.48, for a total value of $207,932.48.
• On Friday, August 21st, Jason Adair sold 73,631 shares of Liquidia stock. The shares were sold at an average price of $69.09, for a total value of $5,087,165.79.

Liquidia Stock Up 0.6%

Shares of LQDA stock traded up $0.28 during mid-day trading on Wednesday, reaching $45.72. 2,235,400 shares of the company were exchanged, compared to its average volume of 2,280,838. Liquidia Corporation has a fifty-two week low of $22.05 and a fifty-two week high of $93.61. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.12 and a current ratio of 2.31. The company has a market capitalization of $4.09 billion, a P/E ratio of 33.37, a P/E/G ratio of 0.37 and a beta of 0.61. The business's 50 day simple moving average is $54.69 and its 200 day simple moving average is $54.15.

Liquidia (NASDAQ:LQDA - Get Free Report) last posted its quarterly earnings results on Wednesday, August 12th. The company reported $0.74 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.76 by ($0.02). Liquidia had a net margin of 30.74% and a return on equity of 149.65%. The company had revenue of $171.68 million during the quarter, compared to analyst estimates of $168.48 million. During the same period in the prior year, the company earned ($0.49) earnings per share. The company's revenue was up 1842.1% on a year-over-year basis. Research analysts predict that Liquidia Corporation will post 2.05 earnings per share for the current year.

Analyst Ratings Changes

LQDA has been the topic of a number of recent analyst reports. Bank of America upped their target price on shares of Liquidia from $79.00 to $92.00 and gave the company a "neutral" rating in a research note on Thursday, August 13th. BTIG Research raised Liquidia from a "neutral" rating to a "buy" rating and set a $70.00 price objective for the company in a report on Wednesday, October 14th. Wall Street Zen downgraded Liquidia from a "buy" rating to a "hold" rating in a report on Saturday, October 3rd. Citigroup reaffirmed a "neutral" rating on shares of Liquidia in a report on Thursday, October 1st. Finally, Piper Sandler set a $129.00 target price on Liquidia in a research report on Friday, July 24th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $72.85.

Hedge Funds Weigh In On Liquidia

A number of large investors have recently bought and sold shares of LQDA. Pinnacle Wealth Planning Services Inc. boosted its stake in Liquidia by 26.2% in the third quarter. Pinnacle Wealth Planning Services Inc. now owns 1,557 shares of the company's stock valued at $47,000 after acquiring an additional 323 shares during the period. Sterling Capital Management LLC grew its holdings in shares of Liquidia by 839.1% during the third quarter. Sterling Capital Management LLC now owns 2,329 shares of the company's stock valued at $70,000 after purchasing an additional 2,081 shares during the last quarter. Nisa Investment Advisors LLC raised its position in shares of Liquidia by 13.8% during the 3rd quarter. Nisa Investment Advisors LLC now owns 2,634 shares of the company's stock worth $80,000 after purchasing an additional 320 shares during the period. Globeflex Capital L P acquired a new stake in shares of Liquidia during the 2nd quarter worth approximately $175,000. Finally, Nykredit A S bought a new stake in shares of Liquidia in the 2nd quarter worth approximately $177,000. Institutional investors own 64.54% of the company's stock.

Liquidia Company Profile

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with pulmonary hypertension and other serious cardiopulmonary diseases. The company is headquartered in Research Triangle Park, North Carolina, and uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition for inhaled and injectable medicines.

Liquidia's lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder formulation of treprostinil delivered through a proprietary inhaler.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.